AJANTA PHARMA Financial Statement Analysis
|
||
|
The Revenues of AJANTA PHARMA have increased by 10.44% YoY .
The Earnings Per Share (EPS) of AJANTA PHARMA has increased by 14.74 % YoY. |
||
AJANTA PHARMA Last 5 Annual Financial Results
[BOM: 532331|NSE : AJANTPHARM]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹4,648 Cr | ₹4,209 Cr | ₹3,743 Cr | ₹3,341 Cr | ₹2,890 Cr |
| Expenses | ₹3,389 Cr | ₹3,037 Cr | ₹2,959 Cr | ₹2,412 Cr | ₹1,891 Cr |
| Operating Profit (Excl OI) | ₹1,260 Cr | ₹1,172 Cr | ₹783 Cr | ₹929 Cr | ₹999 Cr |
| Other Income | ₹95 Cr | ₹85 Cr | ₹99 Cr | ₹116 Cr | ₹26 Cr |
| Interest | ₹21 Cr | ₹7.21 Cr | ₹5.84 Cr | ₹10 Cr | ₹8.27 Cr |
| Depreciation | ₹144 Cr | ₹135 Cr | ₹131 Cr | ₹125 Cr | ₹116 Cr |
| Profit Before Tax | ₹1,189 Cr | ₹1,114 Cr | ₹745 Cr | ₹909 Cr | ₹900 Cr |
| Profit After Tax | ₹920 Cr | ₹816 Cr | ₹588 Cr | ₹713 Cr | ₹654 Cr |
| Consolidated Net Profit | ₹920 Cr | ₹816 Cr | ₹588 Cr | ₹713 Cr | ₹654 Cr |
| Earnings Per Share (Rs) | ₹84.55 | ₹73.69 | ₹64.83 | ₹46.70 | ₹83.45 |
| PAT Margin (%) | 9.35 | 10.34 | 10.23 | 8.20 | 20.99 |
| ROE(%) | 25.42 | 25.06 | 23.49 | 17.68 | 22.77 |
| ROCE(%) | 32.67 | 32.87 | 32.22 | 22.57 | 29.37 |
| Total Debt/Equity(x) | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 39,828.7 Cr |
| Revenue (TTM) | : | ₹ 5,452.9 Cr |
| Net Profit(TTM) | : | ₹ 1,056.0 Cr |
| EPS (TTM) | : | ₹ 84.5 |
| P/E (TTM) | : | 37.7 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| AJANTA PHARMA | 3.4% | 2.7% | 25.2% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.6% | 1.2% | 13% |
| DIVIS LABORATORIES | 1.3% | -2.1% | 3.8% |
| TORRENT PHARMACEUTICALS | 1.5% | 0.7% | 37.1% |
| CIPLA | 6.1% | 2.4% | -5.9% |
| DR REDDYS LABORATORIES | 2.6% | -0.4% | -2.1% |
| MANKIND PHARMA | 7% | 2% | 7.9% |
| LUPIN | 4% | 3.4% | 20.4% |
| ZYDUS LIFESCIENCES | 4.8% | 7% | 13.1% |
AJANTA PHARMA Revenues
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 10.44 % |
| 5 Yr CAGR | 12.62 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹4,648 Cr | 10.44 | |
| Mar2025 | ₹4,209 Cr | 12.45 | |
| Mar2024 | ₹3,743 Cr | 12.02 | |
| Mar2023 | ₹3,341 Cr | 15.62 | |
| Mar2022 | ₹2,890 Cr | - | |
AJANTA PHARMA Operating Profit
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 7.47 % |
| 5 Yr CAGR | 5.98 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,260 Cr | 7.47 | |
| Mar2025 | ₹1,172 Cr | 49.63 | |
| Mar2024 | ₹783 Cr | -15.72 | |
| Mar2023 | ₹929 Cr | -6.94 | |
| Mar2022 | ₹999 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -2.69 % |
| 5 Yr CAGR | -5.90 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 27.1% | -2.69 | |
| Mar2025 | 27.85% | 33.06 | |
| Mar2024 | 20.93% | -24.74 | |
| Mar2023 | 27.81% | -19.53 | |
| Mar2022 | 34.56% | - | |
AJANTA PHARMA Profit After Tax
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 12.77 % |
| 5 Yr CAGR | 8.92 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹920 Cr | 12.77 | |
| Mar2025 | ₹816 Cr | 38.81 | |
| Mar2024 | ₹588 Cr | -17.50 | |
| Mar2023 | ₹713 Cr | 8.99 | |
| Mar2022 | ₹654 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -9.57 % |
| 5 Yr CAGR | -18.30 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 9.35 % | -9.57 | |
| Mar2025 | 10.34 % | 1.08 | |
| Mar2024 | 10.23 % | 24.76 | |
| Mar2023 | 8.2 % | -60.93 | |
| Mar2022 | 20.99 % | - | |
AJANTA PHARMA Earnings Per Share (EPS)
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 14.74 % |
| 5 Yr CAGR | 0.33 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹85 | 14.74 | |
| Mar2025 | ₹74 | 13.67 | |
| Mar2024 | ₹65 | 38.82 | |
| Mar2023 | ₹47 | -44.04 | |
| Mar2022 | ₹83 | - | |
AJANTA PHARMA Return on Capital Employed (ROCE)
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | -0.61 % |
| 5 Yr CAGR | 2.70 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 32.67% | -0.61 | |
| Mar2025 | 32.87% | 2.02 | |
| Mar2024 | 32.22% | 42.76 | |
| Mar2023 | 22.57% | -23.15 | |
| Mar2022 | 29.37% | - | |
AJANTA PHARMA Share Price vs Sensex
| Current Share Price | : | ₹3,188.9 |
| Current MarketCap | : | ₹ 39,828.7 Cr |
| Updated EOD on | : | Jun 23,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AJANTA PHARMA | 3.4% |
2.7% |
25.2% |
| SENSEX | -0.8% |
1.4% |
-6.8% |
AJANTA PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 3.2% | 1.4% | 9.9% |
| BSE 400 MIDSMALLCAP INDEX | 1.3% | 3.1% | 3.3% |
| BSE 150 MIDCAP INDEX | 1% | 2% | 3.9% |
| BSE 1000 | 0.2% | 2.2% | -0.4% |
| BSE 500 | 0.1% | 1.8% | -0.8% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDSMALL HEALTHCARE | 3.7% | 0.9% | 14.7% |
| NIFTY PHARMA | 3.4% | 0.4% | 13.4% |
| NIFTY500 HEALTHCARE INDEX | 3.2% | 0.8% | NA |
| NIFTY MIDSMALLCAP400 50:50 | 1.5% | 3.6% | NA |
| NIFTY 500 EQUAL WEIGHT | 1.3% | 3.9% | 2.9% |
You may also like the below Video Courses
FAQ about AJANTA PHARMA Financials
How the annual revenues of AJANTA PHARMA have changed ?
The Revenues of AJANTA PHARMA have increased by 10.44% YoY .
How the Earnings per Share (EPS) of AJANTA PHARMA have changed?
The Earnings Per Share (EPS) of AJANTA PHARMA has increased by 14.74 % YoY .
Check out Intrinsic Value of Peers of AJANTA PHARMA
Compare Stock Analytics of Peers of AJANTA PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
